Invesco Mutual Fund has launched the Invesco India Pharma and Healthcare Fund, with the New Fund Offer (NFO) open for subscription from August 18 to September 1, 2026. The scheme targets the broad healthcare ecosystem, including pharmaceuticals, hospitals, and diagnostics. Investors should note that sector-specific funds carry higher risks than broad-market funds due to their focus on a single industry.
Invesco Mutual Fund has introduced its latest offering, the Invesco India Pharma and Healthcare Fund, an open-ended equity scheme. The New Fund Offer period, often called an NFO, opened on August 18, 2026, and will remain available for investors to subscribe until September 1, 2026. This fund aims to capture growth opportunities across the entire healthcare spectrum, moving beyond traditional medicine manufacturing to include various service providers.
The fund will be managed by Aditya Khemani, who is also the Head of Equity at the fund house. The performance of the scheme will be measured against the BSE Healthcare Total Return Index. Unlike traditional pharma funds that primarily invest in drug makers, this scheme has a broader mandate. The investment strategy includes hospitals, diagnostic centers, medical device companies, and contract research organizations, alongside businesses providing healthcare insurance.
Investing Beyond Traditional Pharma
The fund house identified several structural growth drivers for the Indian healthcare industry. These include rising healthcare spending by individuals, the expansion of health insurance coverage, an aging population that requires more medical care, and the prevalence of lifestyle-related health conditions. By investing in a range of healthcare-related companies, the fund aims to benefit from the ongoing development of India's medical infrastructure and the country’s role in global pharmaceutical manufacturing and life-sciences innovation.
Understanding Thematic Fund Risks
While the fund offers exposure to a growing sector, it is classified as a thematic fund. This means it invests only in a specific part of the market rather than across many industries like a typical equity fund. For investors, this comes with specific risks. If the healthcare sector underperforms or faces regulatory issues, the fund’s value can drop more sharply than a diversified fund that holds stocks from banks, IT, or manufacturing companies. Investors must be aware that sector-focused schemes are inherently more volatile and sensitive to the specific cycles and policies affecting the pharmaceutical and healthcare business.
Investment Details and Charges
For those interested in participating, the minimum investment amount during the NFO is ₹1,000, with subsequent investments accepted in multiples of ₹1. For those using the Systematic Investment Plan route, the minimum installment starts at ₹100. The fund also has an exit load, which is a fee charged if money is taken out early. A 0.50% exit load will apply if units are redeemed or switched within three months of the allotment date. No exit load will be charged if the investment is held longer than three months. Investors should keep an eye on how the fund manages its portfolio once it begins trading, particularly the balance between established large-cap healthcare stocks and smaller, faster-growing diagnostic or hospital chains.